Laura Shawver Ph.D.
President, CEO, & Director
Laura Shawver Ph.D. is president, chief executive officer, and director of Synthorx. Prior to joining Synthorx, Dr. Shawver held the following positions: CEO and director of Cleave Biosciences, entrepreneur-in-residence for 5AM Ventures, CEO and director of Phenomix Corporation, and president of SUGEN Inc. (acquired by Pharmacia). Shawver has been involved with a number of clinical development programs including two FDA-approved therapies. Shawver is currently a director of Relay Therapeutics as well as an advisor to the industry. She is an active member of the American Association for Cancer Research serving on the Scientific Advisory Committee for Stand Up to Cancer. Shawver knows firsthand what it is like to be a cancer patient. Having survived ovarian cancer, she turned that experience into the founding of The Clearity Foundation, a nonprofit organization providing access to molecular profiling for ovarian cancer patients to improve their treatment options. Shawver received her Ph.D. in pharmacology and a B.S. degree in microbiology both from the University of Iowa.
Marcos Milla, Ph.D.
Senior Vice President of Research
Marcos Milla, Ph.D. is the senior vice president of research at Synthorx. Dr. Milla’s in drug discovery spans across the areas of autoimmunity and inflammation, neurosciences and pain, and immuno-oncology. He has held industry and academic appointments at GlaxoSmithKline, Perelman School of Medicine at the University of Pennsylvania, Roche Palo Alto, Janssen Research & Development, and, most recently, Adaptive Biotechnologies. He has previously directed efforts focusing on multiple intracellular and extracellular target classes, including cell surface and nuclear receptors, ion channels, kinases and proteinases. His work led to the discovery of a break-through series of small molecule modulators of cytokine-receptor interactions. He also explored novel ways of holistically reading pharmacological responses employing high content imaging and gene expression readouts. Dr. Milla graduated with a B.S. degree from Universidad Peruana Cayetano Heredia in Lima, Peru and a Ph.D. degree in cell and molecular biology from Saint Louis University. He did his postdoctoral training at MIT as a Jane Coffin Childs Fellow and at Duke University.
Floyd Romesberg, Ph.D.
Scientific Founder and Director
Floyd E. Romesberg, Ph.D. is the scientific founder and a member of the board of directors of Synthorx. Prior to Synthorx, he served as the scientific co-founder and a member of the board of directors of RQx Pharmaceuticals (acquired by Genentech) and Achaogen, two biopharmaceutical companies focused on developing new antibiotics. Dr. Romesberg is also an associate professor of chemistry at The Scripps Research Institute. His academic research laboratory uses a broad range of interdisciplinary techniques, including non-linear optical spectroscopy, organic chemistry, microbiology, and genetics, to study different aspects of evolution. This work has been described in more than 100 peer-reviewed publications and has been funded by the National Institutes of Health, National Science Foundation, and Office of Naval Research. Dr. Romesberg is best known for developing unnatural base pairs for the expansion of the genetic alphabet and is also working to develop novel antibiotics, as well as to understand how evolution tailors protein dynamics and how cellular stress and DNA damage induce cell-cycle checkpoint responses and mutations. Dr. Romesberg performed his postdoctoral training with Dr. Peter Schultz at the University of California, Berkeley. He received a Ph.D. in physical organic chemistry from Cornell University and a B.S. in chemistry from The Ohio State University.